News & Comment

Improving standards of care and new therapeutics means individuals with cystic fibrosis are living longer, but this brings an increased risk of non-communicable diseases, especially cardiovascular disease (CVD). To improve both longevity and quality of life, it is important to consider CVD risk and prevention in those living with cystic fibrosis.

The intended purpose of machine learning (ML) in cardiovascular medicine is to help guide clinical diagnoses as well as promote scientific discovery. Whether ML is implemented by most clinical cardiologists and cardiovascular researchers will likely depend on the successful resolution of concerns fueling hesitancy to embrace ML. This commentary discusses caveats related to ML in clinical practice, and offers suggestions for stakeholders on how to bridge knowledge gaps and clinicians’ misgivings to bring this powerful approach to the clinic to improve care of the patients we serve.

Nature Cardiovascular Research joins the worldwide effort during the ‘heart month’ of February to raise awareness on how to prevent cardiovascular disease and make healthy lifestyle choices that lead to better cardiovascular health.

With great joy and excitement, we present Nature Cardiovascular Research, a publishing platform and a discussion forum for the most exciting research across the entire spectrum of disciplines focused on cardiovascular and blood physiology and pathology.

How do we measure the impact of scientific research? A new study discusses the current publication culture, diverse animal models that are commonly used in cardiovascular studies, the comparison between basic and clinical research paths, and the role of authors and reviewers in bringing these two paths together.